MED1/BDNF/TrkB pathway is involved in thalamic hemorrhage-induced pain and depression by regulating microglia
Laboratory studyOther animalsHumansWith luteolin (co-ultramicronised PEA plus luteolin, PEALut)
This study tested palmitoylethanolamide together with luteolin (co-ultramicronised PEA plus luteolin, PEALut). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Mice with thalamic haemorrhage induced by collagenase injection; human post-mortem brain specimens after stroke; numbers not stated in the abstract
- Dose used in the study
- Repeated administrations of co-ultramicronised PEALut; dose and route not stated in the abstract
- Duration
- 28-day observation period
- What was measured
- Mechanical hypersensitivity, microglial activation, depressive-like behaviour, synaptic plasticity, monoamine levels and MED1, TrkB and BDNF expression in mice; MED1 in human post-stroke brain tissue.
What the authors reported
This laboratory study found:
- Repeated PEALut significantly reduced mechanical hypersensitivity compared with vehicle, reduced early microglial activation and prevented depressive-like behaviour at 21 days.
- It restored synaptic plasticity, monoamine levels and MED1/TrkB/BDNF expression.
- MED1 was also overexpressed in human brain specimens after stroke.
Limits of this study
A mouse model of post-stroke pain; it cannot show effect in people. Palmitoylethanolamide was combined with luteolin, so PEA alone was not tested. Dose is not in the abstract. Funding and conflicts not stated in the abstract; PEALut is an Epitech Group product.
Source
PubMed 34995755 · doi:10.1016/j.nbd.2022.105611
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.